

## Curriculum vitae

Surname

Rezvani

Name

Mohammad Reza

Nationality

Iranian

Marital status

Married

University studies

B.Sc. in Medical Laboratory Science.

M.Sc. in Haematology .

Ph.D. in experimental Oncology &Haematology.

Post doc. (fellowship) in gene therapy.

Conference and Seminars

Scandinavian Society for Immunology, 11-14 June, Copenhagen, Denmark, 1998). (oral presentation)

VIII International Workshop on CLL (chronic lymphocytic leukemia), 29-31 October, Paris, France (1999).

Poster

American Society of Hematology, Forty-First Annual meeting, December 3-7, New Orleans, LA, USA., ( 1999). (Oral presentation)

Leukemia 2000 towards the cure, September 7-9, Houston, Texas, USA., (2000) (poster)

11<sup>th</sup> International conference of Immunology,  
16-23 July, Stockholm, Sweden. (2001)  
(Poster)

American Society of Hematology, Forty-four  
Annual meeting, December 6-10, Philadelphia,  
pennsylvania, USA., ( 2002).  
(*Oral presentation*)

10<sup>th</sup> congress of European haematology  
association 2-5 June 2005

#### Honorary Awards/PRIZES

I have been awarded as the best second prize of medical basic science article  
by Razi foundation.

#### List of publications

**1-Rezvani M.R.**, Jeddi-Tehrani M., Österborg A., Kimby E., Wigzell H. &  
Mellstedt H. (1999). *Oligoclonal TCR BV Gene Usage in B cell Chronic  
Lymphocytic Leukemia. Major perturbations are preferentially seen within the CD4  
T cell subset. Blood, 94, 1063-1069.*

**2-Rezvani, M.R.**, Jeddi-Tehrani, M., Rabbani, H., Avila-Cariño, J., Österborg, A.,  
Wigzell H., Mellstedt H. (2000) *Autologous T lymphocytes may specifically  
recognize leukaemic B cells in patients with chronic lymphocytic leukemia. Br J  
Haematol 11(2), 608-17, (2000)*

**3-Rezvani, M.R.**, Jeddi-Tehrani, M., Rabbani, H., Rudén, U., Hammarström, L.,  
Österborg, A., Wigzell, H., Mellstedt, H. (2000) *Autologous T lymphocytes*

recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. *British J Haematol* 111(1), 230-38.

**4-Rezvani M.R.**, Jeddi-Tehrani M., Österborg A., Söderlund J., Biberfeld P., Mellstedt H. and Rabbani H. (2001) *Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern*, *British J Haematol* 115(1), 263-271.

**5-Rezvani M.R.**, Jeddi-Tehrani, M., Österborg, A., Wigzell H. and Mellstedt H. *Oligoclonal TCRBV gene usage in chronic lymphocytic leukemia; an analysis of BV gene usage in autologous T cells responding to tumor cells*, (Blood, 2003, vol. 101, no 3, pages 1063-1070).

**6-** Kokhaei P., **Rezvani MR.**, Virving L. Rabbani H, Österborg A. and Mellstedt H. *Dendritic cells loaded with apoptotic tumor cells induce a stronger T cell response than dendritic cell -tumor hybrid in B CLL.* *Lekemia*. 2003 May ; 17 (5): 894-9

7- Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Lundin J, Porwit-MacDonald A, Rossmann ED, Karlsson C, Edman P, **Rezvani MR**, Kimby E, Osterborg A, Mellstedt H. *Leukemia*. 2004 Mar;18(3):484-90.

8- T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Mosolits S, Markovic K, Fagerberg J, Frödin JE, **Rezvani MR**, Kiaii S, Mellstedt H, Jeddi-Tehrani M. *Cancer Immunol Immunother*. 2005 Jun;54(6):557-70.

9-Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M,

**Rezvani MR**, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H. Blood. 2005 Jun 15;105(12):4828-35.

10- Hajjaliasgar S, Agah MR, **Rezvani MR**, Zali MR. CTLA-4 polymorphism at position 49 in exon 1 and susceptibility to type 1 autoimmune hepatitis. *MEDICAL SCIENCES*. 2005; 15 (4) :179-183

11- Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. **Rezvani MR**, Tehrani MJ, Karlsson C, Lundin J, Rabbani H, Osterborg A, Mellstedt H. *Br J Haematol*. 2006 Nov;135(4):475-85.

12-Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. **Rezvani MR**, Kazemi A, Hajifathali A, Kaviani S, Mellstedt H. *Iran Biomed J*. 2007 Apr;11(2):125-9.

13- Frequency of three common mutations of CARD15/NOD2 gene in Iranian IBD patients. Derakhshan F, Naderi N, Farnood A, Firouzi F, Habibi M, **Rezvani MR**, Javeri A, Bahari A, Balaii H, Rad MG, Aghazadeh R, Zali MR. *Indian J Gastroenterol*. 2008 Jan-Feb;27(1):8-11.

14-Repertoire and clonality of T-cell receptor beta variable genes expressed in endometrium and blood T cells of patients with recurrent spontaneous abortion. Dokouhaki P, Moghaddam R, **Rezvani M**, Ghassemi J, Novin MG, Zarnani A, Akhondi MM, Ostadkarampour M, Mellstedt H, Razavi A, Jeddi-Tehrani M. *Am J Reprod Immunol*. 2008 Aug;60(2):160-71.

15-A novel mAb against a human CD34 peptide reacts with the native protein on CD34+ cells. Shams M, Jeddi-Tehrani M, Notash Haghighat F, Bayat AA, Mahmoudian J, **Rezvani MR\***. *Iran J Immunol*. 2013 Dec;10(4):259-66.

16- miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF- $\kappa$ B target genes. Farhadi E, Zaker F, Safa M, **Rezvani MR**. *Tumour Biol*. 2016 Oct;37(10):14117-14128.

17- The effect of cell derived microparticles in transfusion medicine and adaptive immune system, Mohammad Ali Esmaeili<sup>1</sup>, Fatemeh Yari<sup>2</sup>, Ali Amini<sup>1</sup>, **MR Rezvani** \*Received: Arch Med Lab Sci. 2016;2(1):29-35.

18- Investigation of relation between Iron deficiency anemia and hypothyroidism **MR .Rezvani\***, Farhad Malek, Abbas Ghotaslou, Maryam Kamali, Accepted in The Razi Journal of Medical Sciences November 2016.